We studied the @entity137 and efficacy of adding to @entity1259 five resistance modulators in the treatment of resistant solid @entity5 . Additional drugs were added in successive cohorts of @entity1 , such that cohort 1 @entity1 received two drugs along with their @entity1259 , while cohort 4 @entity1 received five modulators along with their @entity1259 . @entity868 , @entity440 (cohort 1), @entity4341 (cohort 2), @entity3102 (cohort 3) and @entity205 (cohort 4) were administered with @entity1259 . A total of 22 @entity1 were treated. @entity390 and @entity391 was usually mild to moderate. There was an unexpectedly high incidence of possible @entity1370 associated with treatment, although in some @entity1 it was uncertain whether or not observed @entity299 were related to treatment. @entity3028 was significant in all four cohorts, but it was unclear whether it was increased by the modulators. There were two febrile neutropenic events in cohorts 1 and 2 successfully treated with antibiotics, and three @entity204 (one in each of cohorts 1, 2 and 4). It was elected to discontinue enrollment on the study prematurely in light of cardiac and other @entity137 seen in the first two @entity1 accrued in cohort 4. A single response was observed. While this approach is feasible, the observed @entity137 and the difficulty @entity1 experienced in ingesting the large number of prescribed pills will make further exploration of this approach difficult.

Pilot study of multiple chemotherapy resistance modulators plus @entity1259 in the treatment of resistant XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity868 :: ('MESH:D008795', 'Chemical') :: ['Metronidazole'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity390 :: ('MESH:D009325', 'Disease') :: ['Nausea'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity3102 :: ('MESH:D007654', 'Chemical') :: ['ketoconazole'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity4341 :: ('MESH:D004176', 'Chemical') :: ['dipyridamole'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity3028 :: ('MESH:D000380', 'Disease') :: ['Granulocytopenia'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiac toxicity'] @entity204 :: ('MESH:D003643', 'Disease') :: ['septic deaths']
@entity5 :: (MESH:D009369,Disease) :: ['malignancies']
